Durata Therapeutics Inc (DRTX) 15.73 $DRTX
Durata Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Fri May 09, 7:31AM CDT
Durata Therapeutics (Nasdaq
RTX) announced today that Paul R. Edick, CEO, will be presenting an overview of the Company at two upcoming investor conferences.
Durata Therapeutics Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) today announced financial results for the quarter ended March 31, 2014.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting
GlobeNewswire - Fri May 02, 7:33AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in six posters at the 24 Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Barcelona, Spain from May 10-13, 2014.
Durata Therapeutics to Announce First Quarter 2014 Financial Results on May 8, 2014
GlobeNewswire - Thu May 01, 9:40AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) has scheduled its quarterly conference call for Thursday, May 8 at 8:30 a.m. Eastern Time to discuss first quarter 2014 financial results.
Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose
GlobeNewswire - Thu Apr 24, 7:30AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of its investigational product, Dalvance(TM) (dalbavancin) for injection, in a single 1500 milligram dose infused over 30 minutes in adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pfizer Blockbuster Zyvox Under Attack
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Incoming competition for Pfizer 's $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company. Recently, an FDA advisory...
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Amy Ho, The Motley Fool - Motley Fool - Fri Apr 04, 5:30PM CDT
Cubist Pharmaceuticals and Durata Therapeutics both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and...
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Durata Therapeutics (DRTX) in Focus: Stock Up 5.64% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:44AM CDT
Durata Therapeutics, Inc. was a big mover last session, as the company saw its shares jump nearly 6% on the day.
Nasdaq stocks posting largest volume increases
AP - Tue Apr 01, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
GlobeNewswire - Mon Mar 31, 4:10PM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 12 to 0 that the Company has provided substantial evidence of the safety and effectiveness of its investigational drug, Dalvance (dalbavancin) for injection, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). While not bound by the guidance provided by the Committee, the FDA will consider the Committee's deliberations as part of its review of the New Drug Application (NDA) for Dalvance, which was accepted for priority review by the FDA in November 2013 with an action date of May 26, 2014.
Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Commit To Purchase Durata Therapeutics At $12.50, Earn 26.4% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:17AM CDT
Investors eyeing a purchase of Durata Therapeutics Inc stock, but cautious about paying the going market price of $14.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
Durata Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Fri May 09, 7:31AM CDT
Durata Therapeutics (Nasdaq
RTX) announced today that Paul R. Edick, CEO, will be presenting an overview of the Company at two upcoming investor conferences. Durata Therapeutics Reports First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 6:08AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) today announced financial results for the quarter ended March 31, 2014. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting
GlobeNewswire - Fri May 02, 7:33AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in six posters at the 24 Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Barcelona, Spain from May 10-13, 2014. Durata Therapeutics to Announce First Quarter 2014 Financial Results on May 8, 2014
GlobeNewswire - Thu May 01, 9:40AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) has scheduled its quarterly conference call for Thursday, May 8 at 8:30 a.m. Eastern Time to discuss first quarter 2014 financial results. Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose
GlobeNewswire - Thu Apr 24, 7:30AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of its investigational product, Dalvance(TM) (dalbavancin) for injection, in a single 1500 milligram dose infused over 30 minutes in adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria. Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pfizer Blockbuster Zyvox Under Attack
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Incoming competition for Pfizer 's $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company. Recently, an FDA advisory...
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Amy Ho, The Motley Fool - Motley Fool - Fri Apr 04, 5:30PM CDT
Cubist Pharmaceuticals and Durata Therapeutics both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and...
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Durata Therapeutics (DRTX) in Focus: Stock Up 5.64% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:44AM CDT
Durata Therapeutics, Inc. was a big mover last session, as the company saw its shares jump nearly 6% on the day.
Nasdaq stocks posting largest volume increases
AP - Tue Apr 01, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
GlobeNewswire - Mon Mar 31, 4:10PM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 12 to 0 that the Company has provided substantial evidence of the safety and effectiveness of its investigational drug, Dalvance (dalbavancin) for injection, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). While not bound by the guidance provided by the Committee, the FDA will consider the Committee's deliberations as part of its review of the New Drug Application (NDA) for Dalvance, which was accepted for priority review by the FDA in November 2013 with an action date of May 26, 2014. Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Commit To Purchase Durata Therapeutics At $12.50, Earn 26.4% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:17AM CDT
Investors eyeing a purchase of Durata Therapeutics Inc stock, but cautious about paying the going market price of $14.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
